Genmab A/S: Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Company Announcement Based on the topline results from the EPCORE NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next steps Data from the clinical

Related Keywords

Copenhagen ,Køavn ,Denmark ,Japan ,Tokyo ,Netherlands ,New Jersey ,United States ,Liz Shea ,Ilke Limoncu ,Mabel Martinez ,Marisol Peron ,Mohamed Zaki ,Andrew Carlsen ,Instagram ,Linkedin ,Twitter ,Global Oncology Development ,Macrophage Properties Journal Of Immunology Baltimore ,Exchange Commission ,Hodgkin Lymphoma Research Foundation ,Youtube ,Us National Library Of Medicine ,Development Of Novel Anti ,Allergan ,Facebook ,Global Investor Relations Communications ,Company Announcement ,Diffuse Large Lymphoma Research Foundation ,Chief Executive Officer ,Vice President ,Allergan Aesthetics ,Annual Report ,Y Shaped Genmab ,Private Securities Litigation Reform Act ,Quarterly Reports ,Largeb Cell Lymphoma ,Research Foundation ,Hodgkin Lymphoma ,England Journal ,Rev Oncol ,Clinically Utilized ,Directed Antibodies ,Macrophage Properties ,Novel Anti Cd ,Cell Surface ,Cancer Science Therapy ,Media Contact ,Senior Vice President ,Investor Relations ,Vie Media Contact ,Vie Investor Relations ,Genmab ,Abbvie ,Nnounce ,Topline ,Results ,Epcoritamab ,Uobody ,D3xcd20 ,Rom ,Hase ,Trial ,Patients ,Relapsed ,Refractory ,Barge ,Fell ,Lymphoma ,Bcl ,